Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06907628RecruitingPhase 1
Testing SHR-3792 for advanced solid tumors
This trial tests a new drug called SHR-3792 for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and how it affects the tumors.
Jinan, ShandongAges 18–75 - NCT05007782RecruitingPhase 1
Testing a new immune drug for advanced solid tumors
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
La Jolla, CaliforniaAges 18 years+ - NCT06895928RecruitingPhase 2
Testing SHR-A2102 for advanced solid tumors
This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–70 - NCT05867420RecruitingPhase 1/Phase 2
ASKG915 for advanced solid tumors that stopped responding
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
New York, New YorkAges 18 years+ - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT05599048RecruitingPhase 1/Phase 2
MRI scan using a special sugar to study solid tumors
This early-phase study tests whether a special MRI scan with injected labeled “pyruvate” can act as a biomarker (a measurable sign) for advanced solid tumor activity. It may help doctors see tumor metabolism over time and better track how treatment is affecting cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06211647RecruitingPhase 1
177Lu XT117 for advanced solid tumors
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
BeijingAges 18 years+ - NCT06927570RecruitingPhase 1
Study of HS-20122 for advanced solid tumors
This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07266285RecruitingPhase 1
Testing BTM-3566 for advanced solid tumors
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT07135128RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
Jinan, ShandongAges 18 years+ - NCT06697197RecruitingPhase 1/Phase 2
Study of experimental drug BMS-986482 for advanced solid tumors
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
Irvine, CaliforniaAges 18 years+ - NCT07348653RecruitingPhase 1
Study of MG2512 for advanced solid tumor patients
This trial tests a new drug called MG2512 for people with advanced solid tumors that have not responded to standard treatments or who cannot take standard therapy. The study aims to understand if MG2512 is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06686745RecruitingPhase 1
Study of an experimental drug alone and with combination for advanced solid tumors
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07539285RecruitingPhase 1
HDM2024 treatment for advanced solid tumors
This study tests a new cancer drug called HDM2024 in people with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have stopped responding to standard treatments. The drug is designed to target specific proteins called EGFR and HER3 on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06672185RecruitingPhase 1
ARC101 for advanced Claudin-6 positive solid tumors
This trial tests a new drug called ARC101 for people with advanced solid tumors that are Claudin-6 positive. It aims to see if the drug is safe and can help shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06618651RecruitingPhase 1
Study of SHR-3821 for advanced solid tumor cancers
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Chengdu, SichuanAges 18–75 - NCT06605222RecruitingPhase 1/Phase 2
Testing SHR-7787 for advanced solid tumors
This trial is testing an investigational drug called SHR-7787 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if it is safe and how well it works. It may be an option if your tumor type is no longer responding to other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06543056RecruitingPhase 2
ES014 for advanced solid tumors
This study tests a new drug called ES014 for people with advanced solid tumors that can't be removed or have spread. It's an early trial to see if ES014 is safe and helps fight certain cancers.
BeijingAges 18 years+ - NCT07455734RecruitingPhase 1/Phase 2
Testing BNT3214 for advanced solid tumors
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
ClaytonAges 18 years+ - NCT07100249RecruitingPhase 1
Study of HDM2012 for advanced solid tumors
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
ShanghaiAges 18–75 - NCT07460375RecruitingPhase 1/Phase 2
Study of LCB02A for advanced solid tumors with Claudin 18.2
This trial tests a new drug called LCB02A, which targets a protein called Claudin 18.2 found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06404905RecruitingPhase 1
Testing BT02 for advanced solid tumors
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
Beijing, BiejingAges 18–75 - NCT06596473RecruitingPhase 1
Study of BG-C477 for advanced solid tumors
This trial tests a new drug called BG-C477 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Goodyear, ArizonaAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,346 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.